Clinical Trial Update: Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload [Phase 2]

View source ↗

Summary

An extension study evaluating the iron chelator deferasirox in patients with transfusional iron overload has completed in Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusional Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Iron Overload | Phase 2 | Status: COMPLETED